<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660762</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-ALL-5010</org_study_id>
    <nct_id>NCT02660762</nct_id>
  </id_info>
  <brief_title>Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL</brief_title>
  <official_title>A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study was conducted to evaluate the efficacy and safety profiles of Modified
      MRCUKALLⅫ/ECOGE2993 Regimen in young adults with newly diagnosed, low-risk, Philadelphia
      chromosome negative acute lymphoblastic leukaemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received a modified BFM regimen which was derived from the MRCUKALLⅫ/ECOGE2993
      Regimen.The differences were as follows:(1) cranial prophylactic radiotherapy was omitted (2)
      Pegaspargase was used instead of L- asparaginase for patient.(3)Two additional Pegaspargase
      treatments were added into consolidation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>every 4 weeks,up to completion of induction treatment(approximately 2months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
    <description>including hematological safety and non-hematological safety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) monitoring</measure>
    <time_frame>During treatment at time point 4, 8, 12, 16,20,24, 28 weeks（every 4 weeks,up to completion of consolidation therapy）and 40，52，64，76，88，100，112，124 weeks( every 12 weeks during maintenance therapy,up to the end of treatment )</time_frame>
    <description>Minimal residual disease is measured in bone marrow using an multiparameter flow cytometry.For the patients who achieved complete remission after induction therapy, if two consecutive tests for MRD were positive,we will define it as MRD positive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukaemia,Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate
,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Vincasar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Cerubidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Prednisone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Methotrexate</intervention_name>
    <description>induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Purinethol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Dexamethasone Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>6-TG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal cytarabine</intervention_name>
    <description>50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.</description>
    <arm_group_label>Modified MRCUKALLⅫ/ECOGE2993 Regimen</arm_group_label>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed ALL

          -  age:18-35years

          -  WBC count below 30×109/L(B lineage)；WBC count below 100×109/L(T lineage)

          -  absence of t(9;22), t(1;19), t(4;11) or any other 11q23 rearrangements

          -  receive no chemotherapy or radiotherapy before

          -  Adequate renal function (eg, serum creatinine≤1.5 mg/dL and creatinine clearance ≥50
             mL minute), and hepatic function (e.g, total bilirubin≤ 2 times the upper limit of
             normal and aspartate and alanine transaminase levels ≤ 3 times the upper limit of
             normal)

        Exclusion Criteria:

          -  mismatch the inclusion criteria

          -  systematic central nervous system involvement, previous or concomitant malignancies
             and any coexisting medical problems that could cause poor compliance with the study
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yue lu, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematological Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hua wang, MD.</last_name>
    <phone>0086-02087342438</phone>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yue lu, MD.</last_name>
      <phone>0086-02087342438</phone>
      <email>dr_luyue@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7. Epub 2005 Aug 16.</citation>
    <PMID>16105981</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>dr. luyue</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

